Oncolytics Biotech Inc ONCY

RE:RE:RE:RE:Roche CD47 antibody start-up gives up-lays off all employees

[Noteable]

In April 2021 ONCY's AWARE-1 demonstrated that " Pelareorep and (Roche's) atezolizumab synergize the anti-cancer immune response in HR+/HER2- breast cancer patients"

• Treatment with pelareorep alone or in combination with atezolizumab increased tumor PD-L1 expression and led to the conversion of PD-L1 negative tumors into PD-L1 positive tumors

"These exciting AWARE-1 data confirm pelareorep promotes a pro-inflammatory tumor microenvironment, allowing it to synergistically interact with checkpoint inhibitors to train the immune system to fight cancer," said Aleix Prat, M.D., Ph.D., Translational Principal Investigator of AWARE-1, SOLTI President and Head of the Medical Oncology Department at Hospital Clinic in Barcelona. "The data show combining pelareorep with anti-PD-L1 therapy led to increases in CelTIL score and an improvement in the ratio between cytotoxic CD8+ T cells to regulatory T cells. These striking immunological changes are associated with greater therapeutic efficacy and improved clinical outcomes. Collectively, the AWARE-1 results highlight pelareorep's potential to address the unmet need for techniques to enhance checkpoint inhibitor efficacy and strongly support the continued clinical evaluation of pelareorep-checkpoint inhibitor combinations."

https://ir.oncolyticsbiotech.com/press-releases/detail/535/oncolytics-biotech-and-solti-achieve-primary-endpoint-in